We are investigating a new antibody-guided drug for patients with therapy-resistant ovarian or lung cancer. The study aims to assess its safety and how well it works compared to existing treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
Platinum-resistant high-grade ovarian cancer is a type of ovarian cancer that does not respond to platinum-based chemotherapy. Similarly, relapsed or refractory adenocarcinoma non-small cell lung cancer (NSCLC) refers to lung cancer that has returned or does not respond to treatment. Both conditions can lead to serious health challenges.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
